The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...

Duxin Sun receives funding from the NIH, FDA, and pharmaceutical industries including Bristol-Myers Squibb, Celgene Corporation, Aurinia Pharmaceuticals, Abbvie, Nanomedicine Innovation Center.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation has teamed up with digital therapeutics specialist Biofourmis to study the effectiveness of patient-centric ...